PDE6B

Across TCGA pan-cancer cohorts, PDE6B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDE6B data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDE6B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PDE6B expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, LSCC, and GBM are the cancer types where PDE6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.390	0.626	.001	17	view →
LSCC	OS	Median	All	1.000	0.922	.012	10	view →
GBM	OS	Tertile	All	0.891	0.641	.013	7	view →
CCRCC	DFS	Tertile	All	1.000	0.538	.023	5	view →
LUAD	OS	Tertile	All	0.932	1.000	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDE6B–PDAC (OS)

Open the PDAC breakdown →